Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Juntendo University Research: Light-activated Protein Treats Parkinson's Disease in a Fly Model


News provided by

Juntendo University

13 Feb, 2020, 07:21 GMT

Share this article

Share toX

Share this article

Share toX

TOKYO, Feb. 13, 2020 /PRNewswire/ -- A light-sensitive protein can restore mitochondria function in fruit flies bearing a gene mutation associated with Parkinson's disease and relieve its symptoms, report researchers at Juntendo University in the journal Communications Biology. The results provide a 'proof of concept' for the approach as a potential treatment for Parkinson's disease.

Related videos
Professor Imai describes this research
https://youtu.be/WVE1fAw90aU

Parkinson's disease is estimated to affect 10 million worldwide, with a prevalence of almost 2 in every 100 among those aged 80 and over. Functional failure in the mitochondria – known as the power houses of cells – is thought to lead to the disease's many symptoms, which primarily impact mobility resulting in shaking, slowness and stiffness, but also include a number of physical, cognitive and psychological symptoms such as nerve pain, dizziness, dementia and depression. Yuzuru Imai and Nobutaka Hattori at Juntendo University and colleagues at the University of Shizuoka and Waseda University in Japan have now developed a light-activated protein, named mito-Delta-rhodopsin (mito-dR), that restores mitochondrion function in a fruit fly model of the disease.

Previous research has pointed towards mutations in the protein coding gene CHCHD2 as the cause of the disease, as well as identifying a number of cellular processes that the disease affects. In terms of energy generating processes, production of ATP – the energy currency in cells – is diminished and the generation of reactive oxygen species increases. Other changes include an accumulation of α-synuclein, a protein mostly found at the tips of neurons, a lack of buffering of the levels of Ca2+ ions, which transfer signals around the nervous system, and ultimately a loss of dopaminergic neurons.

As a model to study the disease, Imai, Hattori and colleagues used Drosophila where the fly's analogue for the CHCHD2 gene was made inoperative (knocked out). They found that decreased ATP production, increased reactive oxygen species, α-synuclein accumulation and loss of Ca2+-buffering, as well as neuron loss all resulted from the genetic modification.

Mitochondrial functions involve the interplay of complex reaction cycles, redox processes and electrochemical forces. In the hope of restoring the lost functions, the researchers examined the effects when the flies were treated with mitochondria designed to express a light-activated proton-transporter protein – Delta-rhodopsin. They found that with exposure to light the mitochondria functions were restored in the flies expressing this protein in cell mitochondria. They also noted the beneficial effects on mitochondrial functions of dopaminergic terminals, increased dopamine production, locomotor activity and flight behavior.

The same functions were not restored in controls expressing mito-dR designed not to respond to light, confirming that the action of the light-activated protein and not the light itself was responsible for the observed recoveries. The researchers conclude that the results provide a 'proof of concept' for a potential therapeutic strategy for Parkinson's disease.

Background

Redox reactions

Reactions that add oxygen atoms to a molecule are called oxidizing reactions and those that reduce the number of oxygen atoms are called reduction reactions. As an extension of their role in these reactions, the transfer of hydrogen ions (H+) and electrons are also described as oxidizing and reducing, or collectively redox, processes. 

Mitochondria and energy

Adenosine triphosphate (ATP) is the chemical responsible for capturing chemical energy from the breakdown of food so that it can be used to fuel the functions of cells throughout the body. Mitochondria produce ATP by oxidizing pyruvate and NADH, the main products of glucose. The process includes a series of reactions called the citric acid cycle. Pyruvate is actively transported across the inner mitochondrial membrane to the mitochondrial matrix where the citric cycle enzymes are found. The citric cycle also produces reduced cofactors that are a source of electrons in the electron transport train.

Small amounts of energy released in the transfer of chemicals that feed into the electron transport chain can be used to pump protons into the intermembrane space, which establishes an electrochemical gradient across the inner membrane. Electrons that prematurely reduce oxygen in this process can lead to reactive oxygen species and cause oxidative stress to the mitochondria, which is related to age-related mitochondrial decline. Conversely proton leak can lower the production of reactive oxygen species and is thought to occur as mitochondrial proton-motive force rises.

Mitochondria can also store Ca2+ ions. Regulating the concentration of these ions affects signal reactions important for signal transduction in the cell. The release of these ions can lead to calcium ion spikes and changes in the membrane potential. It can also trigger the release of neurotransmitters in nerve cells and hormones in endocrine cells.

Delta-rhodopsin

Delta-rhodopsin (dR) is a type of bacteria that thrives in high salt concentrations. It drives unidirectional transmembrane ion transport in response to light through isomerization – a rearrangement of the constituent atoms – of a form of vitamin A known as retinal.

In their control experiments the researchers replace two of the key residues involved in the isomerization with non-functional amino acids. So that the control dR although present was not activated by light.

Reference

Yuzuru Imai, Tsuyoshi Inoshita, Hongrui Meng, Kahori Shiba-Fukushima, Kiyotaka Y. Hara, Naoya Sawamura and Nobutaka Hattori. Light-driven activation of mitochondrial protonmotive force improves motor behaviors in a Drosophila model of Parkinson's disease. Communications Biology, December 2019.

DOI: 10.1038/s42003-019-0674-1

URL: https://doi.org/10.1038/s42003-019-0674-1 

Further information about Juntendo University

Mission Statement

The mission of Juntendo University is to strive for advances in society through education, research, and healthcare, guided by the motto "Jin – I exist as you exist" and the principle of "Fudan Zenshin - Continuously Moving Forward". The spirit of "Jin", which is the ideal of all those who gather at Juntendo University, entails being kind and considerate of others. The principle of "Fudan Zenshin" conveys the belief of the founders that education and research activities will only flourish in an environment of free competition. Our academic environment enables us to educate outstanding students to become healthcare professionals patients can believe in, scientists capable of innovative discoveries and inventions, and global citizens ready to serve society.

History of Juntendo University

Juntendo was originally founded in 1838 as a Dutch School of Medicine at a time when Western medical education was not yet embedded as a normal part of Japanese society. With the creation of Juntendo, the founders hoped to create a place where people could come together with the shared goal of helping society through the powers of medical education and practices. Their aspirations led to the establishment of Juntendo Hospital, the first private hospital in Japan. Through the years the institution's experience and perspective as an institution of higher education and a place of clinical practice has enabled Juntendo University to play an integral role in the shaping of Japanese medical education and practices. Along the way the focus of the institution has also expanded, now consisting of four undergraduate programs and three graduate programs, the university specializes in the fields of health and sports science and nursing health care and sciences, as well as medicine. Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.

Further information
Juntendo University
2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421 JAPAN
E-mail:  release@juntendo.ac.jp
Website: http://www.juntendo.ac.jp/english/
Research: https://www.juntendo.ac.jp/english/research.html

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.